Disagreements Remain In WHO Talks On Virus-Sharing After Chan Proposal 22/10/2009 by Kaitlin Mara for Intellectual Property Watch 2 Comments World Health Organization members this week offered views on the global system for virus- and benefit-sharing for pandemic influenza following recently proposed solutions by Director General Margaret Chan aimed at changing the current, ad-hoc model to a more predictable, sustainably-funded system.
European Union Prepares A New Intellectual Property Rights Strategy 15/10/2009 by Monika Ermert for Intellectual Property Watch 5 Comments Intellectual property rights and their protection will be high on the agenda of the European institutions in the upcoming legislature, representatives from the European Commission, European Council and the European Parliament said at the first European Innovation Summit in Brussels yesterday. Stronger IP rights (IPR) protection was declared by representatives of all three institutions as indispensable to promote innovation and the knowledge society, while only a few voices were raised asking not to overreach in IPR regulation.
Pour les experts, l’accès à des médicaments sûrs est une question de santé publique et non de propriété intellectuelle 15/10/2009 by Catherine Saez, Intellectual Property Watch 1 Comment Selon les participants à un récent événement organisé par Open Society Institute, les initiatives de lutte contre la contrefaçon pourraient limiter l’accès aux traitements sans pour autant réduire le problème des médicaments contrefaits, en particulier dans les pays en développement.
WIPO Members Step Up To Implement Development Agenda 15/10/2009 by Kaitlin Mara for Intellectual Property Watch and William New 1 Comment World Intellectual Property Organisation members are preparing to take the reins of the Development Agenda as it becomes clear that implementation success will depend on their actions. And their actions must not only be focused on specific projects such as patent databases but also on the broader spirit of the agenda for change at WIPO, key developing countries said.
专家组：获取安全药品是公共卫生问题而非知识产权问题 15/10/2009 by Catherine Saez, Intellectual Property Watch Leave a Comment 在最近由开放社会协会（Open Society Institute）主办的一次会议上，与会专家表示，反假冒倡议可能阻碍人们获得药品，但无法解决假药问题，在发展中国家尤其如此。
ITU Panels: Innovation Makes ICTs A Moving Landscape; IP Dispute Resolution Rising 14/10/2009 by Catherine Saez, Intellectual Property Watch Leave a Comment Innovation in information and communications technologies during the economic downturn has brought shifts in the landscape with new technologies and newcomers in the market, according to speakers at a symposium organised by the World Intellectual Property Organization Arbitration and Mediation Center on 8 October. Meanwhile, dispute resolution involving intellectual property rights is on the rise, they said.
Grupo de expertos considera que el acceso a los medicamentos seguros es una cuestión de salud pública y no de propiedad intelectual 14/10/2009 by Catherine Saez, Intellectual Property Watch Leave a Comment Las iniciativas de lucha contra la falsificación podrían dificultar el acceso a los medicamentos sin que se logre paliar el problema de los fármacos falsificados, en particular en los países en desarrollo, según dijeron miembros de un grupo de expertos en un evento organizado recientemente por el Open Society Institute.
WTO Forum: Bypassing International Agreements May Hamper Medicines Access 11/10/2009 by Catherine Saez, Intellectual Property Watch 1 Comment Access to medicines in developing countries may be put at risk by European customs regulations and more broadly by trade provisions in most free trade agreements between developed and developing countries, said speakers at the recent World Trade Organization Public Forum.
Council Of Europe Weighs Future; Drafts Counterfeit Medicines Convention 09/10/2009 by Monika Ermert for Intellectual Property Watch Leave a Comment Sixty years after its foundation, the Council of Europe is reconsidering its role and place in the architecture of European institutions. One new development is the drafting of a convention against medicines counterfeiting.
Biotech Legislative Agenda: Healthcare, Energy, Patents And Capital 05/10/2009 by Liza Porteus Viana, Intellectual Property Watch Leave a Comment The United States Congress and biotechnology industry are currently focused on healthcare reform, but biotech is also looking to the future at energy reform, patent reform and other intellectual property-related legislative priorities still on its agenda.